{"prompt": "['OSTPDL1', 'Page 23 of 60', 'Collaborating Site research participants should be registered at St. Jude', 'within 24 hours of enrollment at the site. The completed Eligibility', 'Checklist and entire signed Informed Consent should be faxed to 901-', '595-6265. Please call 901-595-2568 if confirmation of the enrollment', 'information is needed. The Protocol Eligibility Coordinator will then', 'register the research participant in the Patient Protocol Manager (PPM)', 'system.', '4.0', 'TREATMENT PLAN', '4.1 Overview of Treatment Plan', 'This is a single arm phase 2 study with a two stage design and an', 'endpoint specific to osteosarcoma. Avelumab will be given on days 1 and', '15 of each 4 week cycle. Treatment will be discontinued if there is clear', 'evidence of progression with increase in tumor size greater than 20%, or', 'with drug related dose limiting toxicity that requires removal from', 'therapy, as defined in Section 10.1. Therapy may otherwise continue for a', 'maximum duration of 24 months or 26 cycles, whichever occurs first.', 'Initial radiographic assessments will take place after cycle 2 and cycle 4', 'and will be compared to imaging obtained prior to initiation of therapy.', 'For patients who remain on protocol therapy, imaging thereafter will take', 'place every 3rd cycle.', '4.2', 'Treatment During Cycle 1 and Subsequent Cycles', 'One cycle of avelumab treatment is described below. A cycle may be', 'repeated every 28 days if the patient has at least stable disease and has', 'met laboratory parameters as defined in the eligibility section, and', 'detailed below.', '4.2.1 Premedication', 'In order to mitigate infusion-related reactions, a premedication with an', 'antihistamine and with paracetamol (acetaminophen) 30 to 60', 'minutes prior to each dose of avelumab is mandatory (for example,', '25-50 mg diphenhydramine and 500-650 mg paracetamol IV or oral).', 'This may be modified based on local treatment standards and guidelines,', 'as appropriate.', '4.2.2 Setting', 'Avelumab should be administered in a setting that allows for', 'immediate access to an intensive care unit or equivalent environment', 'and administration of therapy for anaphylaxis, such as the ability to', 'implement immediate resuscitation measures. Steroids', '(dexamethasone 10mg), epinephrine (1:1,000 dilution), allergy', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: RPPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 24 of 60', 'medications (IV antihistamines), bronchodilators, or equivalents, and', 'oxygen should be available for immediate access.', '4.2.3 Observation Period', 'Following avelumab infusions, patients must be observed for 2 hours', 'post-infusion for potential infusion-related reactions.', '4.2.4 Avelumab Administration', 'Prior to avelumab infusion:', 'Diphenhydramine: IV over 5-15 minutes (per institutional guidelines)', 'Days: 1 and 15', 'Dose: 1 mg/kg (MAX 50mg)', 'Note: Equivalent antihistamine therapy may be considered.', 'Acetaminophen: By mouth (PO)', 'Days: 1 and 15', 'Dose: 10-15 mg/kg (MAX 1000mg)', 'Note: In the setting of limited PO intake and per institutional guidelines,', 'IV acetaminophen may be considered.', 'Avelumab infusion:', 'Avelumab: Intravenously over 60 minutes', 'Days: 1 and 15', 'Dose: 10 mg/kg/dose', '4.3', 'Criteria for Starting Subsequent Cycles', 'A cycle may be repeated every 28 days if the patient has again met the', 'parameters for organ function requirements as defined in the eligibility', 'criteria (Section 3.0), has not met any of the criteria for removal from', 'therapy, and has not experienced a dose limiting toxicity. A delay of up', 'to 7 days from the scheduled date of the next scheduled treatment dose', 'may be allowed.', '5.0', 'DOSE MODIFICATIONS FOR TOXICITIES', '5.1 Adverse Drug Reactions Requiring Avelumab Discontinuation or', 'Modification', 'Any Grade 4 ADRs require treatment discontinuation with avelumab except for', 'single laboratory values out of normal range that are unlikely related to study', 'treatment as assessed by the Investigator, do not have any clinical correlate, and', 'resolve within 7 days with adequate medical management.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}